CJC-1295 w/ DAC (20 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

CJC-1295 with DAC (Drug Affinity Complex) is a long-acting analog of growth hormone–releasing hormone (GHRH). The figures below are compiled strictly for laboratory and educational reference — they describe how the compound was handled and dosed across the published research model, not a recommendation for use in humans or animals.

For a 20 mg vial, adding 2.0 mL of bacteriostatic water yields a concentration of 10 mg/mL (10,000 mcg/mL). At that concentration, every 0.10 mL drawn on a U-100 insulin syringe equals 10 units and delivers 1000 mcg of material, so a 500 mcg measurement is simply 0.05 mL, or 5 units — which keeps the arithmetic clean across every titration step.

Standard (Gradual) Titration Schedule

The gradual schedule mirrors the slow dose-escalation pattern used in the research model, where the twice-weekly amount was stepped up by roughly 250 mcg every two weeks to keep exposure measured and reproducible.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab to limit condensation uptake.
2. Draw 2.0 mL of bacteriostatic water and inject it slowly down the inside wall of the vial — never directly onto the powder pellet, and avoid foaming.
3. Swirl or roll the vial gently until fully dissolved. Do not shake; aggressive agitation can shear the peptide.
4. The solution should be clear and colourless. Label the vial with the concentration (10 mg/mL) and the reconstitution date.
5. Store upright under refrigeration (2–8 °C), protected from light, and draw each subsequent volume with a fresh sterile syringe.

Advanced (Aggressive) Titration Schedule

The advanced schedule reaches the top of the researched range more quickly, holding the 1000 mcg twice-weekly ceiling for the bulk of the run rather than ramping over six weeks. It does not exceed the published per-injection band.

Supplies Needed

• CJC-1295 w/ DAC vials (20 mg): roughly 1 vial covers an 8-week run at the standard schedule; 1–2 vials for a 12-week run; ~2 vials for a 16-week aggressive run (one 20 mg vial supplies about 20,000 mcg).
• Insulin syringes (U-100, 1 mL): 16 for an 8-week schedule, 24 for 12 weeks, 32 for 16 weeks — one fresh syringe per twice-weekly draw.
• Bacteriostatic water (10 mL): a single bottle comfortably reconstitutes several 20 mg vials at 2 mL each.
• Alcohol swabs: a single 100-count box covers an 8–16 week schedule.

Protocol Overview

• Research goal: model sustained elevation of growth hormone and IGF-1 via long-acting GHRH-receptor agonism.
• Schedule: twice-weekly subcutaneous administration spaced 3–4 days apart in the published model.
• Dose band: 300–1000 mcg per injection (600–2000 mcg weekly).
• Fill: 20 mg lyophilized, reconstituted to 10 mg/mL with 2 mL diluent.
• Storage: −20 °C dry; 2–8 °C once reconstituted.

Dosing Protocol Notes

• Begin at the 300 mcg per-injection step and raise the amount by roughly 250 mcg every two weeks until the target is reached.
• Maintain a fixed twice-weekly cadence, spaced 3–4 days apart, ideally at a consistent time of day for steady exposure modelling.
• Because the DAC modification provides sustained release, more frequent dosing is unnecessary — the twice-weekly rhythm sustains the curve.
• Run lengths in the model span 8–12 weeks, with optional extension to 16 weeks.
• Rotate sampling/injection sites and document each dose, site and time for reproducibility.

Storage Instructions

Keep sealed lyophilized vials at −20 °C (−4 °F), in dry, dark conditions, where stability extends for many months. Once reconstituted, refrigerate at 2–8 °C (35.6–46.4 °F) and use within about 2–4 weeks. Allow refrigerated solution to warm slightly before drawing, avoid repeated freeze-thaw cycles, and protect from light throughout.

Important Handling Notes

• Allow vials to reach room temperature before opening to reduce condensation uptake.
• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Avoid freeze-thaw cycles on reconstituted material; keep it refrigerated and shielded from light.
• Document each draw — date, volume, remaining material — for reproducibility.

How CJC-1295 w/ DAC Works

CJC-1295 with DAC is a synthetic analog of growth hormone–releasing hormone (GHRH). It binds GHRH receptors on the somatotroph cells of the anterior pituitary and drives growth hormone (GH) release. The DAC component — an albumin-binding moiety — lets the molecule covalently attach to circulating serum albumin, so it persists for days rather than the minutes that native GHRH lasts, extending the effective half-life to approximately 6–8 days. The resulting GH elevation stimulates hepatic IGF-1 production, and IGF-1 in turn mediates many downstream growth and metabolic effects through JAK/STAT signalling. Notably, the underlying pulsatile pattern of GH secretion is preserved even under continuous CJC-1295 stimulation, so the physiological rhythm of release is maintained.

Reported Benefits & Side Effects

Benefits observed in research

• Sustained, dose-dependent elevation of GH and IGF-1 across the dosing interval.
• Associations with increased lean body mass, reduced fat mass and improved body-composition markers.
• Enhanced protein-synthesis and recovery signalling through anabolic pathways.
• Generally well tolerated in the available clinical literature.

Side effects reported

• Occasional mild injection-site reactions such as redness or swelling.
• Transient flushing, headache or water retention reported by some during early titration.
• Effects were generally mild and tended to settle as exposure stabilised.

Supporting Lifestyle Factors (Research Context)

• Protein-forward, micronutrient-dense nutrition as a standard study control.
• Combined resistance and aerobic activity to support lean-mass outcomes.
• Adequate sleep — when most endogenous GH is released — alongside hydration and stress management.

Injection Technique (Reference Only)

• Clean the vial stopper and the site with alcohol swabs and let both dry.
• Pinch a skinfold and insert subcutaneously at a 45–90° angle depending on needle length; aspiration is not required for subcutaneous work.
• Inject slowly and steadily, then wait a few seconds before withdrawing the needle.
• Rotate sites systematically (abdomen, thighs, upper arms), do not rub or massage afterward, and dispose of sharps in an approved container.

References

Related Protocols